Company Overview and News


Add GV
to your dashboard

Headline News

Genomic Vision: First Half 2017 Results

2017-07-26 devicespace
Genomic Vision (Paris:GV) (FR0011799907 – GV), the pioneer of molecular combing technology for life sciences research (LSR) applications and in-vitro diagnostics (IVD), announced today its 2017 first-half financial results to June 30, 20171.

Genomic Vision: (CCG), A Major European Core Facility In Genetic Analysis, Adopts The Molecular Combing Technology

2017-07-13 devicespace
Genomic Vision (Paris:GV) (FR0011799907 – GV), a company specialized in the development of diagnostic solutions for the early detection of cancers and serious genetic diseases and tools for life sciences research today announced the adoption of its molecular combing technology with the use of the FiberVision® platform by the Cologne Center for Genomics (CCG) to further develop the medical biology research and accelerate the discovery of new biomarkers.

Genomic Vision Inks Chinese Distribution Deal With

2017-06-20 devicespace
Genomic Vision (Paris:GV) (FR0011799907 – GV), a company specialized in the development of diagnostic solutions for the early detection of cancers and genetic diseases today announced it has signed a business alliance with APG Bio Ltd to distribute its solutions and services for the life sciences research (LSR) market in Great China, Hong-Kong and Macau.

Genomic Vision, AstraZeneca to Study WEE1 Inhibition Using Molecular Combing

2017-05-23 genengnews
French molecular diagnostics firm Genomic Vision said it is setting up a technology collaboration with AstraZeneca to further evaluate WEE1 kinase inhibition in cancer. The firms will use Genomic Vision’s FiberVision® DNA molecular combing platform to study the effects of AstraZeneca’s WEE1 inhibitor on DNA replication progression in cancer cells, and further investigate how inducing replication stress impacts on the antitumor activity of WEE1 inhibition in cancers with specific genetic backgrounds.

Genomic Vision Hosts Inaugural R&D Day With Its Long-Standing Partner Quest Diagnostics

2017-04-20 devicespace
Genomic Vision (Paris:GV) (FR0011799907 – GV), a biotech company specialized in the development of diagnostic tests for the early detection of cancers and genetic diseases, will host a first R&D Day on May 10th, 2017, in the Imagine Institute (Necker Hospital, Paris).

Genomic Vision Doubles Its Installed Base Of Fibervision Platforms And Quadruples Its Sales Of Products And Services In 2016

2017-01-09 devicespace
Genomic Vision (Paris:GV) (Euronext: FR0011799907 – GV), the DNA molecular combing specialist that develops diagnostic tests and advanced DNA analysis platforms, today reports its revenue and cash position1 at December 31st, 2016.

Genomic Vision Is Accelerating Its Clinical Trial In Cervical Cancer With An Additional Study In The Czech Republic

2016-07-20 devicespace
BAGNEUX, France--(BUSINESS WIRE)--Genomic Vision (FR0011799907 – GV), DNA molecular combing specialist that develops tests for the diagnostics market and tools for the life sciences research market, today announces the first enrollments in the clinical trial being organized in the Czech Republic aimed at validating the integration of the oncogenic, i.e. high-risk, human papillomavirus (HPV-HR) as an indicator of the severity of cervical lesions.

The Clinical Trial Undertaken By Genomic Vision And To Validate A New Test For The Early Detection And Treatment Of Cervical Cancer Was Chosen For An Oral Presentation At The Congress In Salzburg

2016-06-17 devicespace
Genomic Vision (Paris:GV) (FR0011799907 – GV), DNA molecular combing specialist that develops tests for the diagnostics market and tools for the life sciences research market, today announces that the IDAHO clinical trial launched at the end of 2015 in France, which aims to validate the integration of the oncogenic, i.e. high-risk, human papillomavirus (HPV-HR) as an indicator of the severity of cervical lesions and the risk of developing cervical cancer, was presented by Professor Christine Clavel, project coordinator, via an oral presentation at the Eurogin (EUropean Research Organisation on Genital Infection and Neoplasia) Congress held in Salzburg, Austria, from June 15 to 18, 2016.

Global Molecular Diagnostics Market, 2019 - Research and Markets

2016-06-16 prnewswire
Research and Markets has announced the addition of the "Molecular Diagnostics: Infectious Disease, Genetic and Oncology Testing, Market Size, Strategies and Forecasts 2016-2019 - Global Version" report to their offering.

In-Vitro Diagnostic Testing Services Market 2016 Asia-Pacific Trends and Forecasts to 2019 - Research and Markets

2016-05-27 prnewswire
Research and Markets has announced the addition of the "In Vitro Diagnostic Testing Services Market Trends and Forecasts 2016-2019 - Asia Pacific" report to their offering.

European Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market 2016 to 2019 - Research and Markets

2016-05-13 prnewswire
Research and Markets has announced the addition of the "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2016 to 2019 - Europe Version" report to their offering.